Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Other Working Capital Changes (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Other Working Capital Changes for 8 consecutive years, with $13155.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 160.45% year-over-year to $13155.0, compared with a TTM value of -$40172.0 through Dec 2025, up 38.45%, and an annual FY2025 reading of -$75089.0, down 58.8% over the prior year.
  • Other Working Capital Changes was $13155.0 for Q4 2025 at Neuroone Medical Technologies, up from -$91991.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.5 million in Q1 2023 and bottomed at -$1.5 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is $224.25, with a median of -$8714.5 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes crashed 10561.5% in 2022, then soared 66719.23% in 2023.
  • Year by year, Other Working Capital Changes stood at -$13649.0 in 2021, then plummeted by 10561.5% to -$1.5 million in 2022, then soared by 99.74% to -$3780.0 in 2023, then plummeted by 475.71% to -$21762.0 in 2024, then soared by 160.45% to $13155.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for NMTC at $13155.0 in Q4 2025, -$91991.0 in Q3 2025, and $25296.0 in Q2 2025.